1. Home
  2. Labeler Index
  3. Aidarex Pharmaceuticals Llc
  4. 53217-154
  5. Product Images: Tamsulosin Hydrochloride

Product Images Tamsulosin Hydrochloride

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 7 images provide visual information about the product associated with Tamsulosin Hydrochloride NDC 53217-154 by Aidarex Pharmaceuticals Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Chemical Structure - tamsulosin hcl usp 1

Chemical Structure - tamsulosin hcl usp 1

Figure 1 Mean Plasma Tamsulosin Hydrochloride Concentrations Following Single-Dose Administration of Tamsulosin Hydrochloride Capsules 0.4 mg Under Fasted and Fed Conditions (n=8) - tamsulosin hcl usp 2

Figure 1 Mean Plasma Tamsulosin Hydrochloride Concentrations Following Single-Dose Administration of Tamsulosin Hydrochloride Capsules 0.4 mg Under Fasted and Fed Conditions (n=8) - tamsulosin hcl usp 2

This appears to be a figure showing the mean plasma tamsulosin hydrochloride concentrations following single-dose administration of 0.4 mg tamsulosin hydrochloride capsules. The figure shows the concentrations under both fasted and fed conditions over a period of time in hours. Without additional information or context, it's unclear what the specific purpose or findings of this figure are.*

Figure 2A Mean Change from Baseline in Total AUA Symptom Score (0 to 35) Study 1 - tamsulosin hcl usp 3

Figure 2A Mean Change from Baseline in Total AUA Symptom Score (0 to 35) Study 1 - tamsulosin hcl usp 3

This is a graph showing the mean change from the baseline in the total AUA Symptom Score. The study had two groups, one taking treatment and another taking the placebo. The duration of treatment lasted for several weeks. No other information is available.*

Figure 2B Mean Change from Baseline in Total AUA Symptom Score (0 to 35) Study 2 - tamsulosin hcl usp 4

Figure 2B Mean Change from Baseline in Total AUA Symptom Score (0 to 35) Study 2 - tamsulosin hcl usp 4

The figure shows the mean change from the baseline in the total AUA symptom score achieved in Study 2. Treatment groups include O.4mg LNt, O.O8mg LNt, and placebo. The duration of treatment is measured in weeks. No additional information is available.*

Figure 3A Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 1 - tamsulosin hcl usp 5

Figure 3A Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 1 - tamsulosin hcl usp 5

This is a graph (Figure 3A) that shows the mean increase in peak urine flow rate (in L/sec) in Study 1. It compares three different treatments: 0.08 mg, 2x 0.4 mg, and placebo. The mean change in mL/sec is plotted on the y-axis, and the duration of treatment (in weeks) is plotted on the x-axis. The study included a total of 3,380 participants across all treatments.*

Figure 3B Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 2 - tamsulosin hcl usp 6

Figure 3B Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 2 - tamsulosin hcl usp 6

The text appears to show a figure titled "Figure 3B" with the label "Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 2". It includes a chart with a horizontal axis labeled "Duration of Treatment (weeks)" and a vertical axis labeled in "mL/Sec". There is also a legend indicating a treatment group, but the specific details of the values or outcomes are not clear due to the quality.*

Image Description - tamsulosin hcl usp 7

Image Description - tamsulosin hcl usp 7

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.